论文部分内容阅读
罗氏公司1993年在日本和意大利上市了记忆增强药首拉西坦（aniracetam，商品名Draganon），用于治疗老年人因血管和退化原因而引起的记忆和注意力障碍。茵拉西坦是一个败咯烷团衍生物，它能刺激CNS中一些谷氨酸受体，尤其是AMPA和亲代谢的受体。AMPA受体在学习和记忆过程、以及
Roche launched the memory-enhancing drug aniracetam (Draganon) in Japan and Italy in 1993 for the treatment of memory and attention deficits in the elderly due to vascular and degenerative causes. Implants is a racemization derivative that stimulates some of the glutamate receptors in the CNS, particularly AMPA and metabotropic receptors. AMPA receptors in the learning and memory process, as well